The Lancet Oncology in conversation with

5-year quality of life (QOL) substudy of the SUPREMO trial examining the effects of chest wall radiotherapy versus no chest wall radiotherapy after mastectomy in patients with intermediate-risk breast cancer. The data will put patients in a better position to make an informed treatment decision considering long-term QOL effects for intermediate-risk early breast cancer.

Click here to read the full article:

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00122-1/fulltext

Imaging is central to osteosarcoma and Ewing sarcoma diagnosis and treatment, yet no international consensus defines optimal modalities or schedules to date. Hans presents harmonised European recommendations for the imaging of bone sarcomas, fulfilling the requirement for a methodical, systematic, and uniform approach to the diagnosis, treatment response assessment and post-therapy surveillance of osteosarcoma and Ewing sarcoma.

Click here to read the full article: 

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00141-5/fulltext

Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Hedvig Hricak (Memorial Sloan Kettering Cancer Center, New York, NY, USA) and Dr Zachary Ward (Harvard TH Chan School of Public Health, Boston, MA, USA) to discuss Cancer workforce—a global crisis: a Lancet Oncology Commission.

To discover more about the commission click here: www.thelancet.com/commissions-do/cancer-workforce.

To read the full commission click here: https://doi.org/10.1016/S1470-2045(26)00065-3

Cheryl Lai, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Fred Saad (Department of Surgery/Urology, University of Montreal, Montreal, QC, Canada) to discuss pain and health-related quality-of-life outcomes from the randomised phase 3 ARANOTE trial of darolutamide in metastatic hormone-sensitive prostate cancer. Hear about the findings from the study, the importance of quality of life for patients with metastatic prostate cancer, and how clinical research in metastatic hormone-sensitive prostate cancer might look in the next 5 years.

Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00014-8/fulltext

Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Professor James Nagarajah to discuss his open-label, randomised, phase 2 study [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE).

Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00762-4/fulltext

Tell us what you thought about this episode

Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. 

You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv